Guess Who Picked Corbus Pharmaceuticals (NASDAQ:CRBP) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) reported that Stern Adam K has picked up 2,427,250 of common stock as of 2017-03-02.
The acquisition brings the aggregate amount owned by Stern Adam K to a total of 2,427,250 representing a 4.9% stake in the company.
For those not familiar with the company, Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. Its product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis, systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis. Resunab is in Phase II clinical stage for the treatment of Systemic Lupus Erythematosus.
A glance at Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)’s key stats reveals a current market capitalization of 461.19 Million based on 44.44 Million shares outstanding and a price at last close of $9.76 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-22, Cohen picked up 1,340 at a purchase price of $7.64. This brings their total holding to 4,204,562 as of the date of the filing.
On the sell side, the most recent transaction saw Burstein unload 200,000 shares at a sale price of $3.04. This brings their total holding to 3,594,846.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) is Attracting Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) reported that Svlsf Iv, Llc. has picked up 2,579,490 of common stock as of 2017-03-02.
The acquisition brings the aggregate amount owned by Svlsf Iv, Llc. to a total of 2,579,490 representing a 26.6% stake in the company.
For those not familiar with the company, KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
A glance at Kalvista Pharmaceuticals Inc. (NASDAQ:KALV)’s key stats reveals a current market capitalization of 72.55 Million based on 9.93 Million shares outstanding and a price at last close of $7.39 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-04-14, Cha picked up 7,364 at a purchase price of $5.00. This brings their total holding to 4,204,562 as of the date of the filing.
On the sell side, the most recent transaction saw Renzi unload 10,000 shares at a sale price of $3.70. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Perceptive Advisors is Buying Zogenix Inc. (NASDAQ:ZGNX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Zogenix Inc. (NASDAQ:ZGNX) reported that Perceptive Advisors has picked up 1,355,302 of common stock as of 2017-02-22.
The acquisition brings the aggregate amount owned by Perceptive Advisors to a total of 1,355,302 representing a 5.46% stake in the company.
For those not familiar with the company, Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.
A glance at Zogenix Inc. (NASDAQ:ZGNX)’s key stats reveals a current market capitalization of 272.43 million based on 24.79 million shares outstanding and a price at last close of $10.66 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-12-15, Hawley picked up 10,000 at a purchase price of $13.74. This brings their total holding to 90,575 as of the date of the filing.
On the sell side, the most recent transaction saw Shively unload 19 shares at a sale price of $2.00. This brings their total holding to 358,771.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Zogenix Inc. (NASDAQ:ZGNX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Heron Therapeutics Inc. (NASDAQ:HRTX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Heron Therapeutics Inc. (NASDAQ:HRTX) reported that Broadfin Capital has picked up 3,916,534 of common stock as of 2017-02-10.
The acquisition brings the aggregate amount owned by Broadfin Capital to a total of 3,916,534 representing a 9.99% stake in the company.
For those not familiar with the company, Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
A glance at Heron Therapeutics Inc. (NASDAQ:HRTX)’s key stats reveals a current market capitalization of 718.68 million based on 51.47 million shares outstanding and a price at last close of $13.55 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-19, Poyhonen picked up 10,000 at a purchase price of $12.20. This brings their total holding to 10,000 as of the date of the filing.
On the sell side, the most recent transaction saw Rosen unload 12,400 shares at a sale price of $23.89. This brings their total holding to 2,640.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Heron Therapeutics Inc. (NASDAQ:HRTX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Perrigo Co Plc. (NYSE:PRGO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Perrigo Co Plc. (NYSE:PRGO) reported that Starboard Value LP. has picked up 9,641,425 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Starboard Value LP. to a total of 9,641,425 representing a 6.7% stake in the company.
For those not familiar with the company, Perrigo Company plc is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. The company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies.
A glance at Perrigo Co Plc. (NYSE:PRGO)’s key stats reveals a current market capitalization of 11.19 billion based on 143.37 million shares outstanding and a price at last close of $77.76 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-21, Parker picked up 2,500 at a purchase price of $88.75. This brings their total holding to 2,500 as of the date of the filing.
On the sell side, the most recent transaction saw Brown unload 2,097 shares at a sale price of $89.44. This brings their total holding to 10,007.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Perrigo Co Plc. (NYSE:PRGO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.